COVID-19: molecular targets, drug repurposing and new avenues for drug discovery

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as...

Descripción completa

Detalles Bibliográficos
Autores principales: Senger, Mario Roberto, Evangelista, Tereza Cristina Santos, Dantas, Rafael Ferreira, Santana, Marcos Vinicius da Silva, Gonçalves, Luiz Carlos Saramago, de Souza Neto, Lauro Ribeiro, Ferreira, Sabrina Baptista, Silva-Junior, Floriano Paes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Oswaldo Cruz, Ministério da Saúde 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534958/
https://www.ncbi.nlm.nih.gov/pubmed/33027420
http://dx.doi.org/10.1590/0074-02760200254
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within. Finally, we also discuss patent protection issues, cost effectiveness and scalability of synthetic routes for some of the most studied repurposing candidates since these are key aspects to meet global demand for COVID-19 treatment.

Ejemplares similares